Patient enrollment flow chart and the therapeutic course during the 1-year observation after the baseline in our RA cohort.
- Tomohiro Koga (398369)
- Akitomo Okada (4025594)
- Takaaki Fukuda (4025588)
- Toshihiko Hidaka (2634763)
- Tomonori Ishii (186302)
- Yukitaka Ueki (2634766)
- Takao Kodera (4025573)
- Munetoshi Nakashima (398371)
- Yuichi Takahashi (3015525)
- Seiyo Honda (398360)
- Yoshiro Horai (4003178)
- Ryu Watanabe (4025591)
- Hiroshi Okuno (4025576)
- Toshiyuki Aramaki (4003202)
- Tomomasa Izumiyama (4025579)
- Osamu Takai (2131189)
- Taiichiro Miyashita (290199)
- Shuntaro Sato (4025585)
- Shin-ya Kawashiri (4003199)
- Naoki Iwamoto (4003208)
- Kunihiro Ichinose (4003172)
- Mami Tamai (4003175)
- Tomoki Origuchi (739149)
- Hideki Nakamura (1543762)
- Kiyoshi Aoyagi (4025582)
- Katsumi Eguchi (398374)
- Atsushi Kawakami (398370)
Publication date
May 2017
DOIAbstract
<p>HDA: high disease activity; MDA: moderate disease activity; LDA: low disease activity; csDMARDs: conventional synthetic disease-modifying antirheumatic drugs; bDMARDs: biological disease-modifying antirheumatic drugs.</p
Add to ORKG